Kalvista pharmaceuticals, inc. (KALV)
CashFlow / Yearly
Apr'19Apr'18Apr'17Apr'16Dec'15Apr'15Dec'14Dec'13
Cash Flows from Operating Activities
Net loss

-20,816

-15,805

-18,603

-11,436

-

-

-

-

Net loss

-

-

-

-

-24,846

-7,226

-13,359

-5,678

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

378

180

40

33

133

-

54

27

Depreciation expense

-

-

-

-

-

38

-

-

Stock-based compensation expense

2,966

1,060

394

118

785

36

381

238

Realized (gain) from available for sale securities

23

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability and derivative liability

-

-

-

-

-520

-

605

63

Non-cash interest expense

-

-

-

-

-229

-

-64

-32

Amortization of discount/premium on available for sale securities

-

-

-

-

780

-

384

-

Foreign currency exchange gain

80

651

1,371

1,661

-

-

-

-

Loss on extinguishment of convertible promissory notes

-

-

-

-

-3,177

-

-

-

Changes in operating assets and liabilities:
Research and development tax credit receivable

4,883

4,256

600

1,148

-

94

-

-

Grants and other receivables

-

-319

-29

137

-

-

-

-

Prepaid expenses and other current assets

1,979

746

81

475

532

-210

561

46

Other assets

-

123

-

-

-

-

-

-

Grants receivable

-

-

-

-

-

-65

-

-

Other assets

-

-

-

-

97

-

109

-

Accounts payable

1,534

217

-1,599

374

355

167

487

315

Accrued expenses

2,665

1,132

-1,931

1,176

-298

436

830

185

Deferred revenue

-16,127

29,231

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-29

-

-29

6

Net cash used in operating activities

-36,365

10,558

-23,722

-13,156

-

-

-

-

Cash Flows from Investing Activities
Acquisition of property and equipment

1,081

1,427

74

11

659

125

159

18

Net cash provided by (used in) operating activities

-

-

-

-

-20,863

-6,368

-11,253

-4,858

Cash acquired in transaction

-

-

34,139

-

-

-

-

-

Purchases of available for sale securities

79,889

-

-

-

-

-

-

-

Sales and maturities of available for sale securities

11,548

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-69,422

-1,427

34,065

-11

-

-

-

-

Cash Flows from Financing Activities
Proceeds from issuance of common stock from exercise of stock options

242

-

2

-

155

-

229

17

Deposit for leasehold improvements

-

-

-

-

715

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-1,374

-125

-159

-18

Capital lease principal payments

209

151

-

-

-

-

-

-

Issuance of common stock, net of offering expenses

87,910

9,137

-

1

67,908

1

-1,201

-

Net cash provided by financing activities

87,943

8,986

2

33,003

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-1,205

1,988

-1,159

-598

-

-

-

-

Proceeds from convertible promissory notes

-

-

-

-

4,000

-

5,000

-

Proceeds from issuance of convertible preferred stock, net

-

-

-

33,002

-

-

-

6,010

Proceeds from loans payable

-

-

-

-

-

-

2,208

546

Repayment of loan payable

-

-

-

-

-

-

708

158

Net cash from financing activities

-

-

-

-

72,063

8,662

5,528

6,415

Effect of exchange rate changes on cash

-

-

-

-

-

-124

-

-

Net decrease in cash and cash equivalents

-19,049

20,105

9,186

19,238

49,826

2,045

-5,884

1,539

Issuance of preferred stock warrants

-

-

-

-

-

-

103

42

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

347

-

-

-

Conversion of preferred stock and ordinary shares to common stock

-

-

58,613

-

39,556

-

-

-

Capital leases

-

513

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

180

-

626

367

Increase of derivative related to convertible promissory notes

-

-

-

-

1,196

-

1,067

-

Increase of beneficial conversion feature for convertible promissory notes

-

-

-

-

519

-

2,275

-

Acquisition of property and equipment in accounts payable

-

291

-

-

99

-

-

-

Increase accrual of deferred public offering costs

-

-

-

-

-

-

447

-